Investigation of GPR137C as a promising novel marker for the progression of prostate cancer through G4 screen and bioinformatics analyses
Frontiers in Immunology · 2025
DOI: 10.3389/fimmu.2025.1576835 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, 2025. Verfasst von Yue Hou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Military Medical Innovation Center, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biomarkers, Tumor, G-Quadruplexes, Receptors, G-Protein-Coupled. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Prostate cancer (PCa) remains the fifth leading cause of male cancer mortality, necessitating novel biomarkers and therapeutic targets.
Methods
Through BG4 ChIP-seq profiling in PCa cells, we identified promoter G-quadruplex (G4) structures in prognosis-associated genes, with GPR137C exhibiting a functional G4 in its promoter.
Results
This G4 structure facilitates promoter hypomethylation to activate GPR137C transcription. Moreover, GPR137C promotes tumor microenvironment remodeling by enhancing immune cell infiltration, thereby driving PCa progression. Disscussion This study establishes promoter G4s as epigenetic regulators in PCa while proposing GPR137C as both a prognostic biomarker and a therapeutic nexus for GPCR-targeted drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Military Medical Innovation Center, Fourth Military Medical University, Xi'an, China.
- Department of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, Jiangsu, China.
- Reproductive Medical Center, Jinling Hospital Affiliated to Medical School of Nanjing University, Nanjing, Jiangsu, China.
- Department of Urology, Jinhu County Peoples Hospital, Huai'an, Jiangsu, China.
- Department of Bioinformatics, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, China.
Zitieren
APA
Hou, Y., Lu, H., Chen, S., Mao, L., Huang, X., Xu, F., & Shu, C. (2025). Investigation of GPR137C as a promising novel marker for the progression of prostate cancer through G4 screen and bioinformatics analyses. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1576835
Vancouver
Hou Y, Lu H, Chen S, Mao L, Huang X, Xu F, et al. Investigation of GPR137C as a promising novel marker for the progression of prostate cancer through G4 screen and bioinformatics analyses. Frontiers in Immunology. 2025. doi:10.3389/fimmu.2025.1576835
BibTeX
@article{Hou2025,
author = {Hou, Yue and Lu, Haowen and Chen, Saisai and Mao, Likai and Huang, Xuan and Xu, Feng and Shu, Chuanjun},
title = {Investigation of GPR137C as a promising novel marker for the progression of prostate cancer through G4 screen and bioinformatics analyses},
journal = {Frontiers in Immunology},
year = {2025},
doi = {10.3389/fimmu.2025.1576835}
}
EUVIMED